Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa—the Systemic Therapy in Advancing or Metastatic Prostate Cancer:...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	European urology Ročník 67; číslo 6; s. 1028 - 1038
Hlavní autori:	James, Nicholas David, Spears, Melissa R., Clarke, Noel W., Dearnaley, David P., De Bono, Johann S., Gale, Joanna, Hetherington, John, Hoskin, Peter J., Jones, Robert J., Laing, Robert, Lester, Jason F., McLaren, Duncan, Parker, Christopher C., Parmar, Mahesh K.B., Ritchie, Alastair W.S., Russell, J. Martin, Strebel, Räto T., Thalmann, George N., Mason, Malcolm D., Sydes, Matthew R.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland Elsevier B.V 01.06.2015
Predmet:	Adult Age Factors Aged Aged, 80 and over Androgen Antagonists - therapeutic use Cohort Studies Control arm cohort Disease-Free Survival Docetaxel Early Detection of Cancer - mortality Follow-Up Studies Hormone-naïve Humans Kaplan-Meier Estimate Male Metastatic Middle Aged Natural history Neoplasm Grading Neoplasm Metastasis - diagnosis Neoplasm Metastasis - pathology Neoplasm Metastasis - therapy Physical Fitness Prognosis Prognostic factors Proportional Hazards Models Prospective data Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Risk Factors Survival Taxoids - therapeutic use Time to progression Treatment Outcome Urology Control arm cohort Hormone-naïve Time to progression Metastatic Prospective data Prostate cancer Survival Natural history Prognostic factors
ISSN:	0302-2838, 1873-7560, 1873-7560
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!